Brief talking therapies on wards

Not Applicable

Completed

• Conditions: Topic: Mental Health; Subtopic: Psychosis; Disease: Psychosis; Mental and Behavioural Disorders

• Registration Number: ISRCTN37625384
• Lead Sponsor: King's College London

Brief Summary

2016 protocol in http://www.ncbi.nlm.nih.gov/pubmed/27516897 2020 results in https://pubmed.ncbi.nlm.nih.gov/32349698/ (added 25/11/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-08-19
• Study Completion: 2017-12-31
• Last Update Posted: 7 December 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Aged 18 or above
2. Current psychiatric inpatient on a working-age adult ward
3. Diagnosis of schizophrenia-spectrum disorder or psychotic symptoms in the context of an affective disorder (International Statistical Classification of Diseases and Related Health Problems, Tenth edition [ICD-10], F2039)
4. Reports at least one current distressing positive psychotic symptom
5. Able to give informed consent to participate in trial, as assessed by consultant psychiatrist/responsible clinician
6. Willing and able to engage in psychological therapy

Exclusion Criteria

1. Established diagnosis of learning disability, or major cognitive impairment arising from any underlying medical condition (e.g. head injury, neurological disorder) resulting in significant functional impairment
2. Unable to engage in a talking therapy in English, or to complete simple written questionnaires in English
3. Primary diagnosis of substance misuse
4. Does not report any current distressing psychotic symptoms
5. Lacks capacity to consent to participation in research trial
6. Unable to take part in individual therapy due to risk of aggression/violence
7. Mental state precludes possibility of engaging in a talking therapy, e.g. significant thought disorder

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Feasibility/acceptability; Timepoint(s): At trial end (incl. recruitment rate/retention)

Secondary Outcome Measures

Name	Time	Method
<br> 1. Pilot clinical/symptom measures; Timepoint(s): Baseline, Post-therapy, 3 month follow-up, 6 month follow-up<br> 2. Pilot outcome data on re-admission rates; Timepoint(s): 3 and 6 month follow-up<br> 3. Self-ratings of Psychotic Symptoms<br> 4. Hamilton Program for Schizophrenia Voices Questionnaire (HPSVQ)<br> 5. Depression, anxiety and stress scales (DASS-21)<br> 6. Southampton Mindfulness Questionnaire (SMQ)<br> 7. Questionnaire about the Process of Recovery (QPR)<br>